China National Pharmaceutical Group Corporation: Wholly-owned subsidiary Guoyao Weiqida passed the drug GMP compliance inspection.

The announcement from China National Pharmaceutical Group Corporation (Sinopharm) stated that its wholly-owned subsidiary, Sinopharm Witsoda Pharmaceutical Co., Ltd., has received a notice of compliance inspection for drug Good Manufacturing Practice (GMP). The 108 workshop and the comprehensive active pharmaceutical ingredient workshop of Sinopharm Witsoda have passed the GMP compliance inspection. This GMP compliance inspection specifically focused on the active pharmaceutical ingredients and was the first GMP compliance inspection before the product was launched. The workshops and production lines involved are all transformed from old factories, with a total investment of about 22.76 million RMB. The current product being produced on these production lines is acarbose, with a designed annual production capacity of 12 tons.